
Erleada Reduces Risk of Death in Metastatic Prostate Cancer Subset
Among patients with metastatic castration-sensitive prostate cancer, treatment with Erleada (apalutamide) showed consistent 24-month overall survival between real-world use and the phase 3 TITAN trial. These findings were presented at the 50th Annual …